This site is intended for health professionals only
Saturday 19 January 2019
Share |

Topic: Connective tissue disorders

December 21, 2018
The Award encourages exceptional investigators worldwide to pursue innovative research projects that pair unconventional creativity with sound science to uncover the fundamental causes of lupus

The Lupus Research Alliance has announced the 2018 recipients of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: namely, Nir Hacohen, PhD and Vijay Kuchroo, DVM, PhD.

December 17, 2018
Early diagnosis is mandatory in order to start treatment before irreversible tissue damage takes place and this approach results in a better prognosis (that is, less organ damage) and in reduced costs of the disease

 

December 6, 2018
Harmonisation of the diagnostic performance of existing serological assays, finding novel markers to reduce the diagnostic limitation of seronegativity and exploring the predictive value of autoantibodies are the major goals of serodiagnostic research in rheumatoid arthritis

Rheumatoid arthritis (RA) is a prevalent chronic inflammatory autoimmune disease mainly characterised by joint swelling and pain, affecting approximately 0.5–1% of the population in industrialised countries.1

December 6, 2018
Observations from a recent Phase II trial support further development of ustekinumab as a new therapy for SLE, and results from Phase III trials are awaited

Development of new treatments for systemic lupus erythematosus (SLE) has been challenging.

Many components of the immune system have been identified as targets for novel therapies, but the majority of the clinical trials have failed. However, many trials are ongoing and some of them have reported promising preliminary results.

October 2, 2018
In March 2017, the landscape changed significantly for the Ehlers-Danlos syndromes and the newly described hypermobility spectrum disorders
In the last decade, growing attention has been placed on joint hypermobility and related disorders, but the Ehlers-Danlos syndromes (EDS) have fascinated people throughout the ages. The first report of this disorder dates back to Hippocrates (fourth century BC). For many centuries, affected individuals earned their livings as The Elastic Skin Man, The India Rubber Man and The Human Pretzel, amazing their audiences in fairgrounds and circus side shows by exhibiting contortionist tricks and a remarkable ability to stretch their skin.1
 

October 2, 2018
This review focuses on novel treatments in the management of myositis, incuding recent clinical trial data
Idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune muscle disorders including polymyositis (PM), dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM) and possibly inclusion body myositis (IBM). There are some similarities in clinical presentation with proximal symmetric muscle weakness in PM, DM and IMNM; with the exception of IBM, which presents with distal arm and proximal leg asymmetric muscle weakness, finger flexor and knee extensor weakness being characteristic early clinical features of the disease. 
 
October 2, 2018
There is now a better understanding of autoimmunity in systemic lupus erythematosus, which has led to improved therapeutic strategies, but revolutionary treatments have yet to be discovered
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disorder that predominantly affects women of child-bearing age with a ~9:1 female-to-male ratio. Patients with SLE suffer an impaired health-related quality of life (HRQoL), and experience fatigue and pain as major problems. 
 
November 9, 2017
Ustekinumab showed significant improvements in various disease measures compared with placebo, including musculoskeletal, mucocutaneous, immunological markers and flares

Janssen has announced positive results from a randomised, placebo-controlled Phase II study investigating the anti-interleukin (IL)-12/23 monoclonal antibody Stelara® (ustekinumab) in the treatment of active systemic lupus erythematosus (SLE or lupus).

May 8, 2017
New website launched on International Viking Day to support awareness of Viking disease

Today, on International Viking Day, Sobi is launching www.thisisdupuytrens.com to raise awareness of Viking disease, also known as Dupuytren’s disease.

May 13, 2016
On World Lupus Day the National Institute for Health and Care Excellence (NICE) announced a positive recommendation for GSK’s Benlysta® (belimumab) for use in adult patients with active autoantibody positive systemic lupus erythematosus (SLE or ‘lupus’) with a high degree of disease activity despite standard therapy

On World Lupus Day the National Institute for Health and Care Excellence (NICE) announced a positive recommendation for GSK’s Benlysta® (belimumab) for use in adult patients with active autoantibody positive systemic lupus erythematosus (SLE or ‘lupus’) with a high degree of disease activity despite standard therapy.1